Fosun Pharmaceuticals, Borui Pharmaceuticals, and Eddy Pharmaceuticals went up and down when opening

Twenty-seven pharmaceutical companies have been approved to replicate MSD's COVID-19 oral medication. Five of them are Chinese pharmaceutical companies, including Fosun Pharmaceuticals, Shijiazhuang Longze Pharmaceuticals, Shanghai Diseno, and Langhua Pharmaceuticals, a subsidiary of Viabiotics.
$Shanghai Fosun Pharmaceutical (600196.SH)$ $FOSUN PHARMA (02196.HK)$ $Brightgene Bio-Medical Technology Co.,Ltd. (688166.SH)$ $Jiangsu Aidea Pharmaceutical (688488.SH)$